These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 29191821)

  • 1. Follicular bronchiolitis in an HIV-infected individual on combination antiretroviral therapy with low CD4+ cell count but sustained viral suppression.
    Rasmussen LD; Pedersen C; Madsen HD; Laursen CB
    BMJ Case Rep; 2017 Nov; 2017():. PubMed ID: 29191821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cases from the Osler Medical Service at Johns Hopkins University. Diagnosis: P. carinii pneumonia and primary pulmonary sporotrichosis.
    Losman JA; Cavanaugh K
    Am J Med; 2004 Sep; 117(5):353-6. PubMed ID: 15336585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pneumocystis jiroveci pneumonia prophylaxis is not required with a CD4+ T-cell count < 200 cells/microl when viral replication is suppressed.
    D'Egidio GE; Kravcik S; Cooper CL; Cameron DW; Fergusson DA; Angel JB
    AIDS; 2007 Aug; 21(13):1711-5. PubMed ID: 17690568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.
    Srasuebkul P; Ungsedhapand C; Ruxrungtham K; Boyd MA; Phanuphak P; Cooper DA; Law MG
    HIV Med; 2007 Jan; 8(1):46-54. PubMed ID: 17305932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?
    ; Mocroft A; Reiss P; Kirk O; Mussini C; Girardi E; Morlat P; Stephan C; De Wit S; Doerholt K; Ghosn J; Bucher HC; Lundgren JD; Chene G; Miro JM; Furrer H
    Clin Infect Dis; 2010 Sep; 51(5):611-9. PubMed ID: 20645862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meeting the WHO 90% target: antiretroviral treatment efficacy in Poland is associated with baseline clinical patient characteristics.
    Parczewski M; Siwak E; Leszczyszyn-Pynka M; Cielniak I; Burkacka E; Pulik P; Witor A; Muller K; Zasik E; Grzeszczuk A; Jankowska M; Lemańska M; Olczak A; Grąbczewska E; Szymczak A; Gąsiorowski J; Szetela B; Bociąga-Jasik M; Skwara P; Witak-Jędra M; Jabłonowska E; Wójcik-Cichy K; Kamerys J; Janczarek M; Krankowska D; Mikuła T; Kozieł K; Bielec D; Stempkowska J; Kocbach A; Błudzin W; Horban A
    J Int AIDS Soc; 2017 Jul; 20(1):21847. PubMed ID: 28715160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pneumocystis Pneumonia Complicated by Extensive Diffuse Pneumatoceles.
    Albitar HAH; Abu Saleh OM
    Am J Med; 2019 May; 132(5):e562-e563. PubMed ID: 30659808
    [No Abstract]   [Full Text] [Related]  

  • 8. Safety of monitoring antiretroviral therapy response in HIV-1 infection using CD4+ T cell count at long-term intervals.
    Vogler IH; Alfieri DF; Gianjacomo HDB; Almeida ERD; Reiche EMV
    Cad Saude Publica; 2018 Oct; 34(10):e00009618. PubMed ID: 30365742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term immune and virological response in HIV-infected patients receiving antiretroviral therapy.
    Silveira MP; Silveira CP; Guttier MC; Page K; Moreira LB
    J Clin Pharm Ther; 2016 Dec; 41(6):689-694. PubMed ID: 27676134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy.
    Schneider MM; Borleffs JC; Stolk RP; Jaspers CA; Hoepelman AI
    Lancet; 1999 Jan; 353(9148):201-3. PubMed ID: 9923876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group.
    Weverling GJ; Mocroft A; Ledergerber B; Kirk O; Gonzáles-Lahoz J; d'Arminio Monforte A; Proenca R; Phillips AN; Lundgren JD; Reiss P
    Lancet; 1999 Apr; 353(9161):1293-8. PubMed ID: 10218526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Virologic suppression among HIV-infected US Air Force members in a highly-structured programme with free access to care.
    Matthews PE; Le T; Delmar J; Okulicz JF
    Int J STD AIDS; 2015 Nov; 26(13):951-9. PubMed ID: 25505041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy.
    Staszewski S; Miller V; Sabin C; Schlecht C; Gute P; Stamm S; Leder T; Berger A; Weidemann E; Hill A; Phillips A
    AIDS; 1999 May; 13(8):951-6. PubMed ID: 10371176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral therapy-induced increases in CD4+ cell count. A randomized, double-blind, placebo-controlled trial. AIDS Clinical Trials Group 362 Study Team.
    Currier JS; Williams PL; Koletar SL; Cohn SE; Murphy RL; Heald AE; Hafner R; Bassily EL; Lederman HM; Knirsch C; Benson CA; Valdez H; Aberg JA; McCutchan JA
    Ann Intern Med; 2000 Oct; 133(7):493-503. PubMed ID: 11015162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early development of immune reconstitution inflammatory syndrome related to Pneumocystis pneumonia after antiretroviral therapy.
    Mok HP; Hart E; Venkatesan P
    Int J STD AIDS; 2014 Apr; 25(5):373-7. PubMed ID: 24122663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy.
    Hunt PW; Deeks SG; Rodriguez B; Valdez H; Shade SB; Abrams DI; Kitahata MM; Krone M; Neilands TB; Brand RJ; Lederman MM; Martin JN
    AIDS; 2003 Sep; 17(13):1907-15. PubMed ID: 12960823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
    Moore RD; Keruly JC
    Clin Infect Dis; 2007 Feb; 44(3):441-6. PubMed ID: 17205456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recurrence of Pneumocystis carinii pneumonia in an HIV-infected patient: apparent selective immune reconstitution after initiation of antiretroviral therapy.
    Crothers K; Huang L
    HIV Med; 2003 Oct; 4(4):346-9. PubMed ID: 14525547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy.
    Hogg RS; Yip B; Chan KJ; Wood E; Craib KJ; O'Shaughnessy MV; Montaner JS
    JAMA; 2001 Nov; 286(20):2568-77. PubMed ID: 11722271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy.
    Kaufmann GR; Furrer H; Ledergerber B; Perrin L; Opravil M; Vernazza P; Cavassini M; Bernasconi E; Rickenbach M; Hirschel B; Battegay M;
    Clin Infect Dis; 2005 Aug; 41(3):361-72. PubMed ID: 16007534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.